Echo Therapeutics to Present at the JMP Securities Healthcare Conference
Sep. 23, 2010 (PR Newswire) --
FRANKLIN, Mass., Sept. 23 /PRNewswire/ -- Echo Therapeutics, Inc. (OTC Bulletin Board: ECTE), a company developing its needle-free Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and its Prelude™ SkinPrep System for transdermal drug delivery, today announced that Patrick T. Mooney, M.D., CEO, President and Chairman of the Board of Echo Therapeutics will present at the JMP Securities Healthcare Conference being held September 27-28, 2010 at the New York Palace Hotel, 455 Madison Avenue, New York, NY. The Company's presentation is scheduled for 4:30 p.m. ET on September 27, 2010 in the Kennedy I room. Management will be available during the day on September 27 for one-on-one meetings. Please contact your JMP Securities representative to schedule a meeting.
Dr. Mooney will discuss progress of the Company's robust technology platform. Echo Therapeutics recently announced the successful completion of a clinical study to evaluate the ability of Prelude to ablate the skin prior to the application of OTC 4% lidocaine cream for faster-acting local dermal anesthesia. In addition, Echo recently completed the initial product development work on its Prelude SkinPrep System and the Company is now focused on completing the final steps of its regulatory advance to commercialization and leveraging its key strategic partnerships to generate product-related revenue.
About JMP Securities
JMP Securities is a full-service investment bank that provides equity research, institutional brokerage and investment banking services to public and private growth companies and their investors. The firm is a subsidiary of publicly traded JMP Group Inc. (NYSE: JMP).
About Echo Therapeutics
Echo is developing the Symphony tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system for patients with diabetes and for use in hospital critical care units. Echo is also developing its needle-free Prelude SkinPrep System as a platform technology for enhanced skin permeation for delivery of topical pharmaceuticals.
Cautionary Statement Regarding Forward Looking Statements
The statements in this press release that are not historical facts may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, risks related to regulatory approvals and the success of Echo's and its partners' ongoing studies, including the efficacy of Echo's Symphony tCGM and Prelude SkinPrep Systems, the failure of future development and preliminary marketing efforts related to Echo's Symphony tCGM and Prelude SkinPrep Systems, Echo's ability to secure additional commercial partnering arrangements, risks and uncertainties relating to Echo's and its partners' ability to develop, market and sell diagnostic and transdermal drug delivery products based on its skin permeation platform technologies, including the Symphony tCGM and Prelude SkinPrep Systems, the availability of substantial additional equity or debt capital to support its research, development and product commercialization activities, and the success of its research, development, regulatory approval, marketing and distribution plans and strategies, including those plans and strategies related to its Symphony tCGM and Prelude SkinPrep Systems. These and other risks and uncertainties are identified and described in more detail in Echo's filings with the Securities and Exchange Commission, including, without limitation, its annual report on Form 10-K for the year ended December 31, 2009, its quarterly reports on Form 10-Q, and its current reports on Form 8-K. Echo undertakes no obligation to publicly update or revise any forward-looking statements.
For More Information:
Patrick T. Mooney, M.D.
Jeffrey Stanlis
Media: Richard Stern
Chairman and Chief Executive Officer
Partner, Hayden IR
Stern & Co.
(508) 530-0329
(602) 476-1821
(212) 888-0044
SOURCE Echo Therapeutics, Inc.
Patrick T. Mooney, M.D., Chairman and Chief Executive Officer of Echo Therapeutics, Inc., +1-508-530-0329; or Jeffrey Stanlis, Partner, Hayden IR, +1-602-476-1821; or Media, Richard Stern of Stern & Co., +1-212-888-0044, both for Echo Therapeutics, Inc.
Source: PR Newswire (September 23, 2010 - 9:10 AM EDT)
News by QuoteMedia
www.quotemedia.com
